 Prostatic Neoplasms
"Prostatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PROSTATE.
| Descriptor ID |
D011471
|
| MeSH Number(s) |
C04.588.945.440.770 C12.294.260.750 C12.294.565.625 C12.758.409.750
|
| Concept/Terms |
Prostatic Neoplasms- Prostatic Neoplasms
- Prostate Neoplasms
- Neoplasms, Prostate
- Neoplasm, Prostate
- Prostate Neoplasm
- Neoplasms, Prostatic
- Neoplasm, Prostatic
- Prostatic Neoplasm
Prostate Cancer- Prostate Cancer
- Cancer, Prostate
- Cancers, Prostate
- Prostate Cancers
- Cancer of the Prostate
- Prostatic Cancer
- Cancer, Prostatic
- Cancers, Prostatic
- Prostatic Cancers
- Cancer of Prostate
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms".
This graph shows the total number of publications written about "Prostatic Neoplasms" by people in this website by year, and whether "Prostatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1995 | 2 | 1 | 3 | | 1996 | 3 | 0 | 3 | | 1998 | 4 | 0 | 4 | | 2000 | 5 | 0 | 5 | | 2001 | 4 | 0 | 4 | | 2002 | 12 | 1 | 13 | | 2003 | 5 | 3 | 8 | | 2004 | 14 | 3 | 17 | | 2005 | 12 | 1 | 13 | | 2006 | 6 | 3 | 9 | | 2007 | 9 | 1 | 10 | | 2008 | 10 | 1 | 11 | | 2009 | 7 | 2 | 9 | | 2010 | 9 | 1 | 10 | | 2011 | 10 | 0 | 10 | | 2012 | 7 | 0 | 7 | | 2013 | 7 | 1 | 8 | | 2014 | 9 | 2 | 11 | | 2015 | 7 | 4 | 11 | | 2016 | 3 | 0 | 3 | | 2017 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Sturgeon SR, Pilsner JR, Arcaro KF, Ikuma K, Wu H, Kim SM, Chopra-Tandon N, Karpf AR, Ziegler RG, Schairer C, Balasubramanian R, Reckhow DA. White blood cell DNA methylation and risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Breast Cancer Res. 2017 Aug 18; 19(1):94.
-
Ai J, Tai PWL, Lu Y, Li J, Ma H, Su Q, Wei Q, Li H, Gao G. Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue. Prostate. 2017 Sep; 77(12):1265-1270.
-
Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
-
Edmund L, Rotker KL, Lakis NS, Brito JM, Lepe M, Lombardo KA, Renzulli JF, Matoso A. Upgrading and upstaging at radical prostatectomy in the post-prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection? Hum Pathol. 2017 01; 59:87-93.
-
Goel HL, Pursell B, Shultz LD, Greiner DL, Brekken RA, Vander Kooi CW, Mercurio AM. P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. Cell Rep. 2016 Mar 08; 14(9):2193-208.
-
Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA. Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis. 2016 Mar; 37(3):262-8.
-
Wayne EC, Chandrasekaran S, Mitchell MJ, Chan MF, Lee RE, Schaffer CB, King MR. TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer. J Control Release. 2016 Feb 10; 223:215-23.
-
Singh S, Suchard MA. Pioglitazone Use and Risk of Bladder Cancer. JAMA. 2015 Dec 15; 314(23):2567-8.
-
Mak P, Li J, Samanta S, Mercurio AM. ERß regulation of NF-kB activation in prostate cancer is mediated by HIF-1. Oncotarget. 2015 Nov 24; 6(37):40247-54.
-
Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 2015 Dec; 36(6):E1-E150.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|